This is the advice published by the Scottish Medicines Consortium about the use of zoledronic acid for the treatment of osteoporosis in men.
ADVICE: in the absence of a submission from the holder of the marketing authorisation.
zoledronic acid 5mg (Aclasta®) is not recommended for use within NHSScotland for the
treatment of osteoporosis in men at increased risk of fracture, including those with a recent
low-trauma hip fracture.
The holder of the marketing authorisation has not made a submission to SMC regarding this
product in this indication. As a result we cannot recommend its use within NHSScotland.